Imbruvica Leads Sea Change In CLL Landscape
This article was originally published in Scrip
Johnson & Johnson/AbbVie Inc. 's Imbruvica (ibrutinib) has rapidly established itself as standard of care in relapsed/refractory chronic lymphocytic leukaemia and will increasingly move into the first-line setting following its recent approval by the FDA for that use in patients with CLL, analysts say.
You may also be interested in...
With AbbVie's next-generation HCV combo Marivet, newly approved in Europe, the company can look to it and growing sales from Imbruvica to help make up for Humira revenue losses that may start in 2018.
Novartis has withdrawn its label extension application in Europe for use of Arzerra in combination with bendamustine for the treatment of relapsed chronic lymphocytic leukemia, following CHMP queries over a lack of comparable data.
With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.